[Anti-GD2 immunotherapy in patients with high risk neuroblastoma]

Oliva G, Paladio N
Record ID 32010000729
Authors' objectives:

To analyse available scientific knowledge regarding the anti-GD monoclonal antibody in the treatment of patients with high risk neuroblastoma and to assess the possibility of performing this treatment in a reference centre in our country or the inclusion of these patients in international multicenter clinical trials currently underway.

Authors' recommendations: Available scientific evidence on immunotherapy with anti-GD2 in patients with high risk neuroblastoma is limited and low quality (level of evidence 3), its grade of recommendation being of D in accordance with the SIGN system. A certain benefit from treatment with monoclonal antibodies is observed in patients with progression-free disease. At present, this treatment cannot be recommended as standard therapy in patients with high risk neuroblastoma due to the low quality of available scientific knowledge. Taking into account the existence of international multicenter randomized clinical trials currently underway, it is recommended that participation in these studies be always conducted under the scope of a clinical research protocol following all corresponding legal and administrative requirements.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Immunotherapy
  • Neuroblastoma
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.